Stay updated on SAGE-547 for Super-Refractory Status Epilepticus Clinical Trial
Sign up to get notified when there's something new on the SAGE-547 for Super-Refractory Status Epilepticus Clinical Trial page.

Latest updates to the SAGE-547 for Super-Refractory Status Epilepticus Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedA 403 Forbidden page is now shown where the study content would be, indicating the page is blocked from loading the trial information.SummaryDifference16%

- Check24 days agoChange DetectedTel Litwinsky (Israel, 52621) has been added to the list of study sites, while Qiryat Krinitzi (Israel, 52621) has been removed. This reflects an update to the participating locations for the study in Israel.SummaryDifference0.0%

- Check31 days agoChange DetectedA new site entry for Qiryat Krinitzi, Israel, 52621 was added, and Tel Litwinsky, Israel, 52621 was removed from the study locations. This indicates a relocation/expansion of Israel-based sites for the SRSE trial, affecting candidate access and site management.SummaryDifference0.0%

- Check38 days agoChange DetectedThe revision label on the page updates from v3.6.5 to v3.6.6, indicating a minor version update to the page materials. This change does not appear to alter study content or parameters.SummaryDifference0.0%

- Check59 days agoChange DetectedThe page footer now displays Revision: v3.6.5, replacing Revision: v3.6.4. This reflects a minor software update to the page rendering rather than a substantive change to study information.SummaryDifference0.0%

- Check73 days agoChange DetectedThe page now displays Revision: v3.6.4, replacing the previous v3.6.3, indicating a minor platform update.SummaryDifference0.0%

Stay in the know with updates to SAGE-547 for Super-Refractory Status Epilepticus Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SAGE-547 for Super-Refractory Status Epilepticus Clinical Trial page.